Globally, our scientists are committed to transforming molecules into medicines in order to improve the lives of millions of people around the world.
In recent years, we have evaluated and improved our research and development (R&D) methods in order to deliver to patients a sustainable flow of novel medicines and vaccines. As a result, globally, as of 1st of November 2022, we've had 27 Phase 3 clinical trials in progress.1
Source: Pfizer data on file.
Note: This Pfizer Pipeline Snapshot is updated 4 times a year.
Pfizer, as a global organisation, collaborates with scientists, technicians, regulatory professionals and business experts across the world, including those in the UK, to find and develop the next generation of innovative medicines for patients.
As part of our approach, we also work with other innovators across the health landscape including academic scientists, patient organisations, governments, other biopharmaceutical companies and healthcare professionals.
We focus our efforts in core areas where we are best positioned to develop medicines for much needed therapies. This includes chronic inflammatory and autoimmune diseases, vaccines, oncology, pain, cardiovascular and metabolic disease and rare diseases.
Clinical trials are an essential step in the medicine development process.
Our medicines save and transform the lives of millions around the world every year, but developing them is a complicated process.